IL224813B - Compositions comprising th1 killer cells and uses thereof - Google Patents

Compositions comprising th1 killer cells and uses thereof

Info

Publication number
IL224813B
IL224813B IL224813A IL22481313A IL224813B IL 224813 B IL224813 B IL 224813B IL 224813 A IL224813 A IL 224813A IL 22481313 A IL22481313 A IL 22481313A IL 224813 B IL224813 B IL 224813B
Authority
IL
Israel
Prior art keywords
cells
preparations containing
killer
containing killer
preparations
Prior art date
Application number
IL224813A
Other languages
English (en)
Hebrew (he)
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of IL224813B publication Critical patent/IL224813B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL224813A 2010-08-20 2013-02-19 Compositions comprising th1 killer cells and uses thereof IL224813B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40188110P 2010-08-20 2010-08-20
US201161495055P 2011-06-09 2011-06-09
PCT/US2011/048578 WO2012024666A2 (en) 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties

Publications (1)

Publication Number Publication Date
IL224813B true IL224813B (en) 2020-06-30

Family

ID=45594250

Family Applications (1)

Application Number Title Priority Date Filing Date
IL224813A IL224813B (en) 2010-08-20 2013-02-19 Compositions comprising th1 killer cells and uses thereof

Country Status (19)

Country Link
US (3) US20120045423A1 (https=)
EP (1) EP2606125B1 (https=)
JP (2) JP6408219B2 (https=)
KR (1) KR101900807B1 (https=)
CN (2) CN103068973A (https=)
AU (1) AU2011291477B2 (https=)
BR (1) BR112013003989B1 (https=)
CA (1) CA2808873C (https=)
DK (1) DK2606125T3 (https=)
ES (1) ES2660577T3 (https=)
HU (1) HUE036094T2 (https=)
IL (1) IL224813B (https=)
NO (1) NO2606125T3 (https=)
PH (1) PH12013500519B1 (https=)
PL (1) PL2606125T3 (https=)
PT (1) PT2606125T (https=)
SG (2) SG10201510524TA (https=)
TR (1) TR201802334T4 (https=)
WO (1) WO2012024666A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660577T3 (es) * 2010-08-20 2018-03-23 Immunovative Therapies, Ltd. Células que expresan características y propiedades citolíticas de Th1
KR101697473B1 (ko) * 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
AU2019381526B2 (en) 2018-11-14 2023-02-23 Green Cross Lab Cell Corporation Method for culturing cord blood-derived natural killer cells using transformed T-cells
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
US11730313B2 (en) * 2021-02-24 2023-08-22 Kirsten Wilkins Slow cooker liner system with integrated dividers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050392A1 (en) * 1998-09-22 2003-03-13 Brother Kogyo Kabushiki Kaisha Water-based ink for ink jetting and ink jet recording method
US20030194395A1 (en) * 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
AU2002341717A1 (en) 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
ES2340270T3 (es) 2002-08-23 2010-06-01 Gabriele Prof. Dr. Multhoff Granzima b dependiente de peptidos hsp70/hsp70 como inductora de apoptosis en celulas tumorales.
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
CA2555714C (en) * 2004-02-26 2013-12-03 Immunovative Therapies, Ltd. Methods for preparing t-cells for cell therapy
ES2660577T3 (es) 2010-08-20 2018-03-23 Immunovative Therapies, Ltd. Células que expresan características y propiedades citolíticas de Th1

Also Published As

Publication number Publication date
NO2606125T3 (https=) 2018-04-21
JP2013536232A (ja) 2013-09-19
CN103068973A (zh) 2013-04-24
KR20130103485A (ko) 2013-09-23
US20130195825A1 (en) 2013-08-01
BR112013003989B1 (pt) 2020-11-24
JP2017061558A (ja) 2017-03-30
SG10201510524TA (en) 2016-01-28
EP2606125A4 (en) 2014-03-19
AU2011291477B2 (en) 2016-07-28
PH12013500519A1 (en) 2013-05-06
JP6408219B2 (ja) 2018-10-17
US20130196428A1 (en) 2013-08-01
PT2606125T (pt) 2018-02-27
EP2606125B1 (en) 2017-11-22
PH12013500519B1 (en) 2020-06-26
AU2011291477A1 (en) 2013-04-04
SG187846A1 (en) 2013-03-28
CA2808873A1 (en) 2012-02-23
DK2606125T3 (en) 2018-03-05
PL2606125T3 (pl) 2018-05-30
CA2808873C (en) 2020-02-18
ES2660577T3 (es) 2018-03-23
US20120045423A1 (en) 2012-02-23
KR101900807B1 (ko) 2018-11-08
BR112013003989A2 (pt) 2017-11-14
CN108245673A (zh) 2018-07-06
US10385315B2 (en) 2019-08-20
WO2012024666A3 (en) 2012-05-18
EP2606125A2 (en) 2013-06-26
WO2012024666A2 (en) 2012-02-23
JP6525946B2 (ja) 2019-06-05
TR201802334T4 (tr) 2018-03-21
HUE036094T2 (hu) 2018-06-28

Similar Documents

Publication Publication Date Title
IL282198A (en) Compositions of functional mitochondria and uses thereof
IL286784A (en) Compositions of protein and antibody
IL250259A0 (en) Compositions comprising ursolic acid and derivatives thereof and uses thereof
SMT201600218B (it) Batterio per uso come probiotico per applicazioni nutrizionali e mediche
IL230662A0 (en) Indazoles
DK2838548T5 (en) Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
PL2606120T4 (pl) Ludzkie komórki ułatwiające tolerancję i ich zastosowanie
HUE054437T2 (hu) Anti-CGRP készítmények és alkalmazásuk
HRP20170983T1 (hr) Pripravci s visokom koncentracijom antitijela
EP2870505A4 (en) TRANSPARENT GLOSS AND GLOSS PROTECTION STRUCTURES
HRP20181447T1 (hr) Pripravci glp-1 peptida i njihova priprava
SG11201408697QA (en) Methods and compositions for natural killer cells
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
IL226307A0 (en) Compounds and methods for treating pain
EP2770899A4 (en) TISSUE AND CELLULAR IMAGING
EP2742123A4 (en) ISOLATION AND DETECTION OF CANCER CELLS
PL2552484T3 (pl) Sposoby i preparaty służące do zmniejszenia poziomu hormonu przytarczyc
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
IL223667B (en) S100a4 antibodies and therapeutic uses thereof
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
BR112012028633A2 (pt) composição reticulada e artigo
IL224813B (en) Compositions comprising th1 killer cells and uses thereof
IL222343A0 (en) Compositions comprising allogeneic th1 cells and uses thereof
IL229956B (en) Mphosphi peptides and vaccines including the same
EP2912164A4 (en) MICRO-RNAS AND CELL PROGRAMMING

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed